Dear Attendee:

On behalf of the FDA Oncology Center of Excellence and the American Cancer Society, we want to thank you for your interest in setting benchmarks for diversity in clinical trials. Due to an unexpected development, this event will be rescheduled. We look forward to providing you with additional details about the future symposium. We are excited to have this opportunity to truly advance oncology clinical trial diversity.

The American Cancer Society would like to thank our sponsors for their generous support of the diversity in clinical trials symposium. Thank you to Merck, Gilead, and Pfizer.

*FDA does not endorse or support any fundraising activities in connection with this event. All sponsorship will go solely toward the event expenses of ACS, not FDA.